abstract |
(57) [Summary]nThe present invention, in combination with a non-interferon polypeptide with Th2-enhanced cytokine activity, induces oral tolerance to bystander antigens and suppresses autoimmune reactions in combination with by-products such as myelin basic protein or proteolipid protein. It is a method for treating autoimmune diseases such as multiple sclerosis by orally administering a standard antigen. |